

| | | | | | |
|--|---|----|---|--------------------------|------------------|
| IDS Form PTO/SB/08: Substitute for form 1449A/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 09/884,526 |
| Sheet | 1 | of | 1 | Filing Date | June 19, 2001 |
| | | | | First Named Inventor | David MEEKER |
| | | | | Art Unit | 1632 |
| | | | | Examiner Name | Shin Lin CHEN |
| | | | | Attorney Docket Number | 07680.0019-00000 |

| U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS | | | | | |
|--|-----------------------|--|---|---|---|
| Examiner Initials | Cite No. ¹ | Document Number | Issue or Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

| FOREIGN PATENT DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--------------------------------|---|---|
| Examiner Initials | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|--|-----------------------|---|--|--|--------------------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | Translation ⁶ |
| <i>SL</i> | | Ziegler et al., Mol. Ther. 9:231-240 (2004). AAV2 Vector Harboring a Liver-Restricted Promoter Facilitates Sustained Expression of Therapeutic Levels of α -Galactosidase A and the Induction of Immune Tolerance in Fabry Mice. | | | |
| <i>SL</i> | | Barbon et al., Mol. Ther. 12:431-440 (2004). AAV8-Mediated Hepatic Expression of Acid Sphingomyelinase Corrects the Metabolic Defect in the Visceral Organs of a Mouse Model of Niemann-Pick Disease. | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| | | | |
|--------------------|----------------------|-----------------|---------------|
| Examiner Signature | <i>Shin-Lin Chen</i> | Date Considered | <i>3-1-06</i> |
|--------------------|----------------------|-----------------|---------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.